1. Clinical & Scientific Overview
Etizolam, Chlordiazepoxide & Clobazam (TIP-MED-000454, Reference Code [11.18]) is classified under
Neurology Medicines as a Thienodiazepine, Long-Acting 1,4-Benzodiazepine & 1,5-Benzodiazepine Anxiolytics/Anticonvulsant (Schedule H1 / H | NLEM 2022 [Clobazam]).
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 (Rx — 3-Year Register Retention & Red-Border Warning).
Representative Indian Formulations (for identification only): Etizolam: Etilaam (Intas), Etizola (Macleods), Macfresh; FDCs with Escitalopram or Propranolol. Chlordiazepoxide: Librium (Abbott), Equilibrium; | Strengths: Etizolam Tablets / MD: 0.25 mg, 0.5 mg, 1 mg. Chlordiazepoxide Tablets: 10 mg, 25 mg. Clobazam Tablets: 5 mg, 10 mg, 20 mg
Standard hospital formulary strengths
3. Mechanism of Action & Pharmacodynamics
Established pharmacological class action (Thienodiazepine, Long-Acting 1,4-Benzodiazepine & 1,5-Benzodiazepine Anxiolytics/Anticonvulsant (Schedule H1 / H | NLEM 2022 [Clobazam])): targets primary receptor, enzyme, ion-channel, or cellular pathway to achieve therapeutic efficacy in Etizolam: Short-term management (<=2–4 weeks) of acute anxiety and panic attacks.
4. Therapeutic Indications & Evidence-Supported Uses
- Etizolam: Short-term management (<=2–4 weeks) of acute anxiety and panic attacks
- Chlordiazepoxide: First-line long-acting benzodiazepine for Acute Alcohol Withdrawal Syndrome / Delirium Tremens prophylaxis (CIWA-Ar symptom-triggered or fixed 5–7 day taper — active metabolites desmethyldiazepam/oxazepam provide smooth
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Etizolam: 0.25–0.5 mg PO BD or HS (Max 1.5–2 mg/day for <=2–4 weeks). Chlordiazepoxide (Alcohol Withdrawal): Day 1: 25–50 mg PO q6h (+ Thiamine 100–500 mg IV/PO!), then taper by 20–25% daily over 5–7 days and STOP. Clobazam (Epilepsy): Start 5–10 mg PO at bedtime, titrate to 10–20 mg BD (Max 40–60 mg/day) (Duration: Etizolam: <=2–4 weeks; Chlordiazepoxide: 5–7 day alcohol detox taper; Clobazam: Chronic epilepsy adjunct (never stop Clobazam abruptly in epilepsy — precipitates status epilepticus!))
Administration & Meal Timing: Oral (PO) | Food & Meal Timing: May be taken with or without food | Best Time of Day: Bedtime or BD (q6h tapering for Chlordiazepoxide in alcohol detox)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Hospital pharmacokinetic profile; monitor therapeutic response and organ clearance.
Renal: Start at lowest dose in severe CKD. Hepatic: AVOID Chlordiazepoxide in Child–Pugh B/C cirrhosis (switch to Lorazepam!); reduce Clobazam & Etizolam by 50%
Renal: Start at lowest dose in severe CKD. Hepatic: AVOID Chlordiazepoxide in Child–Pugh B/C cirrhosis (switch to Lorazepam!); reduce Clobazam & Etizolam by 50%
Renal: Start at lowest dose in severe CKD. Hepatic: AVOID Chlordiazepoxide in Child–Pugh B/C cirrhosis (switch to Lorazepam!); reduce Clobazam & Etizolam by 50%
7. Contraindications, Precautions & High-Risk Warnings
- CONTRAINDICATED in myasthenia gravis, severe respiratory insufficiency, severe sleep apnoea, and acute narrow-angle glaucoma
- Note: In Cirrhosis / Alcoholic Liver Disease with Jaundice or Ascites, Chlordiazepoxide (half-life >100h via CYP450) accumulates and precipitates hepatic coma — use **Lorazepam** (glucuronidated, non-CYP) for alcoh
Key Clinical Precautions: High-alert hospital specialist agent; administer under close physiological and laboratory monitoring.
8. Adverse Effects Profile
- Drowsiness, fatigue, ataxia, dizziness, anterograde amnesia, dependence and rebound insomnia/anxiety on abrupt withdrawal
- Monitor for hemodynamic instability, organ toxicity, or severe hypersensitivity.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Active metabolite of Clobazam (N-desmethylclobazam) is cleared by CYP2C19: Potent CYP2C19 inhibitors (Fluconazole, Fluvoxamine, Omeprazole, Esomeprazole, Cannabidiol) increase N-desmethylclobazam levels 3–5-fold -> profound sedation & ataxia! CYP3A4 inhibitors (Itraconazole, Clarithromycin) increase
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Continuous clinical, hemodynamic, and organ-function laboratory monitoring.
Pharmacist Patient Counselling Points:
- COUNTER CHECKS: (1) Never stop Frisium (Clobazam) suddenly in epilepsy (triggers continuous seizures)
- (2) For Etilaam (Etizolam), use only for 2–4 weeks while long-term SSRI takes effect, then taper off slowly
Storage, Stability & Dispensing Safeguards: Store in original moisture-protected packaging below 25°C–30°C (or 2°C–8°C cold chain if parenteral/biological vial specified in strengths: Etizolam Tablets / MD: 0.25 mg, 0.5 mg, 1 mg. Chlordiazepoxide Tablets: 10 mg, 25 mg. Clobazam Tablets: 5 mg, 10 mg, 20 mg). Missed-Dose Rule: In epilepsy (Frisium), take missed dose as soon as remembered; in anxiety, do not double dose
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO • NCBI Bookshelf
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [11.28] Sumatriptan, Rizatriptan & Betahistine / Cinnarizine / Flunarizine — 5-HT1B/1D Receptor Agonist Acute Migraine Triptans & Vestibular/M
- [3.1] Amlodipine (as Amlodipine Besylate) — Dihydropyridine Calcium Channel Blocker (CCB); Arterial Vasodilat
- [11.16] Nortriptyline & Clomipramine Hydrochloride — Secondary & Tertiary Amine Tricyclic Antidepressants — TCAs (Sche
- [11.23] Trihexyphenidyl (Benzhexol) Hydrochloride — Centrally Acting Antimuscarinic (M1) Anticholinergic for Drug-Ind